The companies will evaluate and execute product development programs directed at immune stimulation and disease prevention in a variety of animal species. In addition, the agreement anticipates that Bayer Animal Health will help financially support Juvaris’s research, product formulation, development and GMP manufacturing activities to support its alliance obligations. The license is worldwide in scope.
Lykele van der Broek, president of Animal Health Division, Bayer, said: “The beauty about this cooperation is, that it is not just about one single product. It serves as a platform technology that helps us develop a wide range of applications in several species for numerous indications in preventing infectious diseases. This technology in combination with our in-house expertise dramatically expands our ability to develop new and innovative products that promote immune stimulation and disease prevention.”